Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1975 2
1977 1
1978 1
1979 1
1981 1
1982 3
1983 5
1984 3
1985 3
1986 4
1987 5
1988 3
1989 7
1990 2
1991 7
1992 10
1993 11
1994 13
1995 20
1996 23
1997 25
1998 38
1999 37
2000 36
2001 42
2002 39
2003 51
2004 32
2005 49
2006 63
2007 44
2008 53
2009 65
2010 72
2011 72
2012 63
2013 91
2014 81
2015 79
2016 77
2017 72
2018 84
2019 89
2020 91
2021 93
2022 58
2023 34
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

1,586 results

Results by year

Filters applied: . Clear all
Page 1
Cryoglobulinemia Vasculitis.
Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cacoub P, et al. Am J Med. 2015 Sep;128(9):950-5. doi: 10.1016/j.amjmed.2015.02.017. Epub 2015 Mar 30. Am J Med. 2015. PMID: 25837517 Review.
The 10-year survival rates are 63%, 65%, and 87% in HCV-positive mixed CryoVas, HCV-negative mixed CryoVas, and type I CryoVas patients, respectively. In HCV-positive patients, baseline poor prognostic factors include the presence of severe liver fibrosis, and central nerv …
The 10-year survival rates are 63%, 65%, and 87% in HCV-positive mixed CryoVas, HCV-negative mixed CryoVas, and type I CryoVas patients, res …
Cold agglutinin disease revisited: a multinational, observational study of 232 patients.
Berentsen S, Barcellini W, D'Sa S, Randen U, Tvedt THA, Fattizzo B, Haukås E, Kell M, Brudevold R, Dahm AEA, Dalgaard J, Frøen H, Hallstensen RF, Jæger PH, Hjorth-Hansen H, Małecka A, Oksman M, Rolke J, Sekhar M, Sørbø JH, Tjønnfjord E, Tsykunova G, Tjønnfjord GE. Berentsen S, et al. Blood. 2020 Jul 23;136(4):480-488. doi: 10.1182/blood.2020005674. Blood. 2020. PMID: 32374875 Free article. Clinical Trial.
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C. van Rhee F, et al. Lancet Oncol. 2014 Aug;15(9):966-74. doi: 10.1016/S1470-2045(14)70319-5. Epub 2014 Jul 17. Lancet Oncol. 2014. PMID: 25042199 Clinical Trial.
Unicentric Castleman Disease.
Wong RSM. Wong RSM. Hematol Oncol Clin North Am. 2018 Feb;32(1):65-73. doi: 10.1016/j.hoc.2017.09.006. Hematol Oncol Clin North Am. 2018. PMID: 29157620 Review.
Breast Implant-associated Anaplastic Large Cell Lymphoma.
Alotaibi S, Hamadani M, Al-Mansour M, Aljurf M. Alotaibi S, et al. Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):e272-e276. doi: 10.1016/j.clml.2020.12.005. Epub 2020 Dec 13. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33384263 Free article. Review.
Malignancies After Heart Transplant.
Lateef N, Abdul Basit K, Abbasi N, Kazmi SM, Ansari AB, Shah M. Lateef N, et al. Exp Clin Transplant. 2016 Feb;14(1):12-6. doi: 10.6002/ect.2015.0214. Epub 2015 Dec 1. Exp Clin Transplant. 2016. PMID: 26643469 Free article. Review.
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP. Vincenti F, et al. Am J Transplant. 2010 Mar;10(3):535-46. doi: 10.1111/j.1600-6143.2009.03005.x. Am J Transplant. 2010. PMID: 20415897 Free article. Clinical Trial.
Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options.
Faye A, Vilmer E. Faye A, et al. Paediatr Drugs. 2005;7(1):55-65. doi: 10.2165/00148581-200507010-00005. Paediatr Drugs. 2005. PMID: 15777111 Review.
These therapeutic approaches need to be further evaluated, especially in the context of pre-emptive strategies adapted to predictive markers of EBV-induced PTLD....
These therapeutic approaches need to be further evaluated, especially in the context of pre-emptive strategies adapted to predictive …
1,586 results